| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash flows provided by (used in) investing activities | 12,761,027 | 6,832,489 |
| Net proceeds from the issuance of common stock, net of issuance costs of 30,722 | 958,339 | - |
| Proceeds from warrant exercises | - | 0 |
| Proceeds from option exercises | 13,442 | - |
| Net cash flows provided by financing activities | 971,781 | 0 |
| Effect of foreign exchange rates on cash | 30,466 | 30,727 |
| Change in cash and cash equivalents for the period | 878,407 | -1,449,671 |
| Cash and cash equivalents at beginning of period | 7,511,079 | - |
| Cash and cash equivalents at end of period | 8,389,486 | - |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)